Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Affiliations

• ¹ Leukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. [email protected].
• ² Leukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
• ³ Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
• ⁴ Research Institute Children's Cancer Center Hamburg, Hamburg and Department of Pediatric Oncology and Hematology, University Medical Center, 20246, Hamburg, Germany.
• ⁵ Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden.
• ⁶ Department of Clinical Genetics and Pathology and Molecular Diagnostics, Laboratory Medicine, Region Skåne, Lund, Sweden.
• ⁷ Department of Clinical Immunology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
• ⁸ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
• ⁹ Department of Paediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
• ¹⁰ Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
• ¹¹ Department of Haematology, Bristol Children's Hospital, Bristol, UK.
• ¹² Astrid Lindgren Children's Hospital, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.